Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata 05/07/2018 Medications WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Read more